IP Library Granted Patent US 8,110,540
Granted Patent B2
US 8,110,540 · App. 12/700,526 · Granted Feb 7, 2012

Antigen delivery vectors and constructs

Assignee: Immune Targeting Systems Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,110,540
App. No.
12/700,526
Granted
Feb 7, 2012
Kind
B2
Abstract

The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

Claims (23)

1. A composition comprising:

a fluorocarbon vector-antigen construct of structure C m F n —C y H x -(Sp)-R, where m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3−30 and Sp is an optional chemical spacer moiety and R is an immunogenic peptide comprising an antigen selected from the group consisting of a viral antigen, a bacterial antigen, a parasitic antigen, and a cancer antigen; and

one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

2. The composition of claim 1 , wherein the fluorocarbon vector-antigen construct has a structure

3. The composition of claim 1 , wherein the fluorocarbon vector-antigen construct has a structure

4. The composition of claim 1 , wherein the fluorocarbon vector-antigen construct has a structure

5. The composition of claim 1 , wherein R comprises one or more epitopes from a viral protein.

6. The composition of claim 1 , wherein R is a peptide consisting of between 7 to 70 amino acids.

7. The composition of claim 1 , wherein R comprises at least one B cell epitope.

8. The composition of claim 1 , wherein R comprises two or more overlapping epitopes.

9. The composition of claim 1 , wherein the fluorocarbon vector is non-covalently associated with an antigen.

10. The composition of claim 1 , wherein R comprises multiple epitopes and/or fusion peptides.

11. The composition of claim 1 formulated for parenteral, oral, ocular, rectal, nasal, transdermal, topical, or vaginal administration.

12. The composition of claim 1 , wherein the composition is a liquid, solid, aerosol or gas.

13. The composition of claim 1 comprising an adjuvant selected from the group consisting of muramyldipeptide (MDP) derivatives, CpG, monophosphoryl lipid A, oil in water adjuvants, water-in-oil adjuvants, aluminium salts, immunostimulating complex (ISCOMs), liposomes, microparticles, saponins, cytokines, bacterial toxins and toxoids.

14. The composition of claim 1 , wherein the immunogenic peptide defines a T-cell epitope.

15. A composition comprising:

a fluorocarbon vector-antigen construct of structure C m F n —C y H x -(Sp)-R, where m=3 to 30, n<=2m+1, y=0 to 15, x<=2y, (m+y)=3−30, Sp is an optional chemical spacer moiety, and R is an immunogenic peptide defining a T-cell epitope; and

one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

16. The composition of claim 15 , wherein the fluorocarbon vector-antigen construct has a structure

17. The composition of claim 15 , wherein the fluorocarbon vector-antigen construct has a structure

18. The composition of claim 15 , wherein the fluorocarbon vector-antigen construct has a structure

19. The composition of claim 15 , wherein the epitope is from a viral protein.

Assignments (3)
CHANGE OF NAME Recorded Nov 10, 2015
From: VAXIN UK LIMITED
To: ALTIMMUNE UK LIMITED
Reel/Frame 037083/0588 →
CHANGE OF NAME Recorded Jul 16, 2015
From: IMMUNE TARGETING SYSTEMS (ITS) LIMITED
To: VAXIN UK LIMITED
Reel/Frame 036125/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2010
From: BONNET, DOMINIQUE; BROWN, CARLTON B.; GEORGES, BERTRAND; SIZER, PHILIP J.
To: IMMUNE TARGETING SYSTEMS LTD.
Reel/Frame 025040/0609 →
Priority Claims (1)
GB 0408164.2 · Apr 13, 2004 · national
Continuity (2)
Continuation 11096725 · Apr 1, 2005
Related Publication 20100183650A1 · Jul 22, 2010